Core Viewpoint - The company has received a notice of acceptance from the National Medical Products Administration (NMPA) for its clinical trial application of the fixed combination nasal spray, Olopatadine Mometasone, marking a significant step in its clinical development process [1][2] Group 1: Product Development - The product is a self-developed fixed combination nasal spray aimed at treating moderate to severe allergic rhinitis in specific age groups [1] - The formulation combines an antihistamine (Olopatadine) for allergy symptoms and a corticosteroid (Mometasone) for inflammation-related symptoms, potentially offering a convenient treatment option for patients who do not respond well to single therapies [1][2] - The fixed combination formulation is designed to reduce the need for patients to use multiple products, thereby enhancing medication convenience and adherence [1] Group 2: Strategic Importance - Advancing this product is deemed significant for expanding the company's nasal care product portfolio, potentially providing broader treatment options for moderate to severe patients upon approval [2] - The project highlights the company's R&D capabilities in nasal suspension formulations and drug-device integration, which typically have higher technical barriers and quality requirements compared to standard formulations [2] - Once approved, the product could complement the existing respiratory and nasal product lineup, strengthening market coverage in the airway disease treatment sector [2]
长风药业：奥洛他定莫米松鼻喷雾剂临床试验申请获NMPA受理